The role of temozolomide as adjuvant therapy in glioblastoma management: a systematic review and meta-analysis.

Abstract Introduction The persistent challenge of temozolomide (TMZ) resistance and the eventual recurrence of tumors underscore the need for ongoing research and the development of novel therapeutic strategies. We aim to consolidate existing evidence related to the safety and efficacy of TMZ as adj...

Full description

Bibliographic Details
Published in:	BMC Cancer
Main Authors:	Made Agus Mahendra Inggas, Utsav Patel, Jeremiah Hilkiah Wijaya, Nina Otinashvili, Vyshnav Rajagopal Menon, Abhay Krishnan Iyer, Tawfiq Turjman, Surbhi Dadwal, Mari Gadaevi, Azada Ismayilova, Shiva Jashwanth Gaddam, Prakriti Arya, Nihar Upadhyay, Saurabh Kataria
Format:	Article
Language:	English
Published:	BMC 2025-03-01
Subjects:	Glioblastoma Overall survival Progression free survival Temozolomide.
Online Access:	https://doi.org/10.1186/s12885-025-13757-1

Similar Items

Comparison of multi-cycle and standard-cycle temozolomide chemotherapies in patients with glioblastoma undergoing surgery and successive radiotherapy
by: Yuan Fu, et al.
Published: (2023-06-01)

Resveratrol and temozolomide induce apoptosis and suppress proliferation in glioblastoma cells via the apoptotic signaling pathway
by: Görkem Tutal Gürsoy, et al.
Published: (2025-08-01)

The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma multiforme: a meta-analysis and systematic review
by: Ehsan Alimohammadi, et al.
Published: (2020-02-01)

Temozolomide (TMZ) in the Treatment of Glioblastoma Multiforme—A Literature Review and Clinical Outcomes
by: Marcin Jezierzański, et al.
Published: (2024-07-01)

Efficacy and safety of metformin plus low-dose temozolomide in patients with recurrent or refractory glioblastoma: a randomized, prospective, multicenter, double-blind, controlled, phase 2 trial (KNOG-1501 study)
by: Wan-Soo Yoon, et al.
Published: (2023-06-01)

Retrospective Study of the Safety and Efficacy of Anlotinib Combined With Dose-Dense Temozolomide in Patients With Recurrent Glioblastoma
by: Lei She, et al.
Published: (2021-07-01)

Temozolomide in treatment resistant prolactinomas
by: V. N. Shree, et al.
Published: (2018-08-01)

Comparative proteogenomic characterization of glioblastoma
by: Samia Asif, et al.
Published: (2019-06-01)

MGMT methylation pattern of long-term and short-term survivors of glioblastoma reveals CpGs of the enhancer region to be of high prognostic value
by: Henning Leske, et al.
Published: (2023-08-01)

Methylation associated with long- or short-term survival in glioblastoma patients from the Nordic phase 3 trial
by: Małgorzata Łysiak, et al.
Published: (2022-08-01)

The Impact of Surgery in IDH 1 Wild Type Glioblastoma in Relation With the MGMT Deregulation
by: Francesco Marchi, et al.
Published: (2020-01-01)

The Impact of <i>MGMT</i> Promoter Methylation and Temozolomide Treatment in Serbian Patients with Primary Glioblastoma
by: Nikola Jovanović, et al.
Published: (2019-02-01)

Quinacrine enhances temozolomide cytotoxicity in temozolomide-sensitive and -resistant glioblastoma cells
by: Pingde Zhang, et al.
Published: (2018-01-01)

Importance of Autophagy Regulation in Glioblastoma with Temozolomide Resistance
by: Young Keun Hwang, et al.
Published: (2024-08-01)

Temozolomide for aggressive pituitary tumors:-A literature review
by: Hu Hui-zheng, et al.
Published: (2024-02-01)

Temozolomide Resistance in Glioblastoma by NRF2: Protecting the Evil
by: Karoline Almeida Lima, et al.
Published: (2023-04-01)

Dose and Efficacy of Bevacizumab in Recurrent High-Grade Gliomas: A Retrospective Study
by: Bai X, et al.
Published: (2024-11-01)

Extended dosing (12 cycles) vs conventional dosing (6 cycles) of adjuvant temozolomide in adults with newly diagnosed high-grade gliomas: a randomized, single-blind, two-arm, parallel-group controlled trial
by: Kazem Anvari, et al.
Published: (2024-05-01)

Outcomes of pediatric glioblastoma treated with adjuvant chemoradiation with temozolomide and correlation with prognostic factors
by: Supriya Mallick, et al.
Published: (2015-01-01)

Response to Temozolomide in patients with metastatic melanoma in a third level medical facility
by: Selene Mejía-Cabrera, et al.
Published: (2022-03-01)

A Multicenter Randomized Bioequivalence Study of a Novel Ready-to-Use Temozolomide Oral Suspension vs. Temozolomide Capsules
by: François Ducray, et al.
Published: (2023-11-01)

Overcoming temozolomide resistance in glioma: recent advances and mechanistic insights
by: Hengzeng Li, et al.
Published: (2025-06-01)

Molecular Mechanisms of KDELC2 on Glioblastoma Tumorigenesis and Temozolomide Resistance
by: Yu-Ling Tsai, et al.
Published: (2020-09-01)

Temozolomide Chronotherapy in Glioma: A Systematic Review
by: Jason L. Jia, et al.
Published: (2023-02-01)

S-1/temozolomide versus S-1/temozolomide plus thalidomide in advanced pancreatic and non-pancreatic neuroendocrine tumours (STEM): A randomised, open-label, multicentre phase 2 trial
by: Yihebali Chi, et al.
Published: (2022-12-01)

Long term survival in a patient with recurrent metastatic Ewing sarcoma treated with irinotecan and temozolomide
by: Hakan Gelincik, et al.
Published: (2016-12-01)

Vincristine, Irinotecan, and Temozolomide in Patients With Relapsed/Refractory Neuroblastoma
by: Jia Zhu, et al.
Published: (2022-03-01)

Integrins and p53 pathways in glioblastoma resistance to temozolomide
by: Monique eDontenwill, et al.
Published: (2012-10-01)

Targeting of temozolomide using magnetic nanobeads: an in vitro study
by: Berna Gürten, et al.
Published: (2020-09-01)

Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years
by: Makoto Ohno, et al.
Published: (2019-11-01)

Down-Regulation of CEND1 Expression Contributes to The Progression and Temozolomide Resistance of Glioma
by: Houjun Zhou, et al.
Published: (2023-04-01)

TTK Protein Kinase promotes temozolomide resistance through inducing autophagy in glioblastoma
by: Jian Yu, et al.
Published: (2022-07-01)

Temozolomide-associated blepharoconjunctivitis: a case report
by: Tom Kornhauser, et al.
Published: (2024-04-01)

Meningeal seeding from glioblastoma multiforme treated with radiotherapy and temozolomide
by: Lu-Ting Kuo, et al.
Published: (2017-01-01)

Is Autophagy Inhibition in Combination with Temozolomide a Therapeutically Viable Strategy?
by: Ahmed M. Elshazly, et al.
Published: (2023-02-01)

Should CD4 Levels be Monitored in a Patient on Temozolomide?
by: Sriram Gonakoti, et al.
Published: (2021-03-01)

99mTc-Tetrofosmin uptake correlates with the sensitivity of glioblastoma cell lines to temozolomide
by: George Alexiou, et al.
Published: (2017-01-01)

Pediatric Non–Brain Stem High-Grade Glioma: A Single-Center Experience
by: Ehsan Alimohammadi, et al.
Published: (2020-06-01)

Prognostic factors for glioblastoma: a retrospective single-center analysis of 176 adults
by: HUANG Guohao, et al.
Published: (2024-09-01)

Expression of STAT3 and hypoxia markers in long-term surviving malignant glioma patients
by: Katerina Dvorakova, et al.
Published: (2024-04-01)